TABLE 3.
Resistance evaluations for strains AR351 and I0003-1 a
| Treatment regimen | I0003-1: resistance at 24 h in biofilm TKAs | Treatment regimen | AR351: resistance at 24-h biofilm TKAs | ||
|---|---|---|---|---|---|
| CIP MIC | 14207 | CIP MIC | EM | ||
| Monotherapies | Monotherapies | ||||
| CIP | 2 | Not tested | CIP | 1 | Not tested |
| 14207 | Not tested | R | EM | Not tested | R |
| Multiple antibiotics | Multiple antibiotics | ||||
| MEM + CIP | 1 | Not tested | MEM + CIP | 1 | Not tested |
| AZT + CIP | 1 | Not tested | AZT + CIP | 1 | Not tested |
| AMK + CIP | 1 | Not tested | AMK + CIP | 1 | Not tested |
| COL + CIP | 1 | Not tested | COL + CIP | 1 | Not tested |
| PACs | PACs | ||||
| 14207 + CIP | 1 | S | EM + CIP | 0.5 | S |
| 14207 + COL + CIP | 0.125 | S | EM + COL + CIP | 0.5 | S |
| 14207 + AMK + CIP | 0.125 | S | EM + AMK + CIP | 0.5 | S |
| 14207 + MEM + CIP | 0.25 | S | EM + MEM + CIP | 0.5 | S |
| 14207 + AZT + CIP | 0.125 | S | EM + AZT + CIP | 1 | R |
a
Antibiotic and phage resistance testing results after 24 or 96 h for biofilm time-kill analyses and biofilm models, respectively.COL, colistin; MEM, meropenem; AMK, amikacin; CIP, ciprofloxacin; AZT, aztreonam; MIC, minimum inhibitory concentration; 14207, 14207 phage; EM, phage EM-T3762627-2_AH; EC, phage E2005-C; 109, 109 phage; PACs, phage-antibiotic combinations; S, sensitive defined as <10 CFU in spot; R, resistant defined as no visible effect of phage versus phosphate-buffered saline control.